Blog

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of … – MarketWatch

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of …
MarketWatch
Instrumental in our ability to achieve this milestone are JDRF, the leading global organization focused on type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine, a leading organization focused on advancing stem cell …

and more »

2014-08-19 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.